In an attempt to mitigate the hyperinflammatory cytokine storm associated with COVID-19, janus kinase/signal transducer and activator of transcription (JAK/STAT) inhibitors baricitinib, ruxolitinib, and tofacitinib have been investigated as potential therapeutics. The gene discussed is SOAT1; the disease is COVID-19.